# Bart Dzikowski

> Bart Dzikowski is a startup investor at Novartis Venture Fund (Basel). See 0 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Novartis Venture Fund](https://shizune.co/investors/profile/novartis-venture-fund)
- Location: Basel, Switzerland
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/bart-dzikowski-421668a

Bart Dzikowski is a startup investor at Novartis Venture Fund in Basel. Bart Dzikowski is the Head of Legal for NVF in Basel, Switzerland. During his time with Novartis, he has served as the Head of Corporate Legal M&A (a.i.) and as Senior Business Development & Licensing/M&A Counsel. Before joining Novartis in 2009, Bart was Vice President with the Investment Banking Division of Bank ofAmerica/Merrill Lynch in New York and, before that, he was an associate with the Corporate/M&A Group at the law firm of Allen & Overy LLP in New York. Bart holds degrees in common law (LL.B.) and civil law (B.C.L.) from McGill Law School in Canada and is a member of the New York State Bar.

## About Novartis Venture Fund

VC Fund · Basel, Switzerland

Novartis Venture Fund's primary focus is on the development of novel therapeutics and platforms. They balance the therapeutic focus with investments in medical devices, diagnostics, or drug delivery systems. In their investments, they look for unmet needs and clinical impact, novel proprietary science, an understanding of mechanism, managementand board experience, and capital efficiency in the program.Novartis Venture Fund prefers to have their initial investment at the early stage to build the company and follow with additional investment in pace with the company's progress. Their approach involves larger focused investments, with anticipation of total investments up to USD 30 to 50 million per company over its life, but it can be as little as 100,000 USD to get started. They plan to increase their activities to lead or co-lead deals further and remain open to participating in larger syndicates.

5 contacts available at Novartis Venture Fund.

| Name | Title | Profile |
| --- | --- | --- |
| Aaron Nelson | Principal & Managing Director | https://shizune.co/investors/profile/aaron-nelson |
| Anja König | Global Head Novartis Venture Fund | https://shizune.co/investors/profile/dr-anja-knig |
| Bart Dzikowski | Managing Director, Head of Transactions & Legal | https://shizune.co/investors/profile/bart-dzikowski |
| Florent Gros | Managing Director | https://shizune.co/investors/profile/florent-gros |
| Florent Gros | Managing Director | https://shizune.co/investors/profile/florent-gros-4c33 |

## FAQ

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co